慢性阻塞性肺疾病合并肺动脉高压患者血栓素A2（TXA2）和前列环素（PGI2）的变化
[Changes of thromboxane A2 (TXA2) and prostacyclin (PGI2) in COPD patients with pulmonary hypertension].
作者信息
Zheng L, Duan S F, Zhang Z X
机构信息
Department of Respiratory Diseases, Affiliated Tongji Hospital, Tongji Medical University, Wuhan.
出版信息
Zhonghua Nei Ke Za Zhi. 1991 Feb;30(2):91-3, 126.
We measured the pulmonary arterial pressure and the level of Thromboxane A2 (TXA2), and Prostacyclin (PGI2) in 30 stable COPD patients and the level of TXA2 and PGI2 in 10 normal subjects so as to investigate the changes of TXA2 and PGI2 in COPD patients with pulmonary hypertension. The results showed that the level of TXA2 increased significantly in COPD patients with dominant and latent pulmonary hypertension when compared with that in normal subjects (P less than 0.001, less than 0.01), and the level of TXA2 in COPD patients with dominant pulmonary hypertension was also higher than that in COPD patients with latent pulmonary hypertension (P less than 0.02), but there was no difference in the level of PGI2 among normal subjects and COPD patients with or without pulmonary hypertension. This indicates that TXA2 plays an important role in causing pulmonary hypertension in COPD patients.
我们测量了30例稳定期慢性阻塞性肺疾病（COPD）患者的肺动脉压以及血栓素A2（TXA2）和前列环素（PGI2）水平，并测量了10名正常受试者的TXA2和PGI2水平，以研究合并肺动脉高压的COPD患者中TXA2和PGI2的变化。结果显示，与正常受试者相比，显性和隐性肺动脉高压的COPD患者TXA2水平显著升高（P<0.001，<0.01），显性肺动脉高压的COPD患者TXA2水平也高于隐性肺动脉高压的COPD患者（P<0.02），但正常受试者以及合并或不合并肺动脉高压的COPD患者之间PGI2水平无差异。这表明TXA2在COPD患者肺动脉高压的发生中起重要作用。
Zotero 插件